Form 4: Stoke Therapeutics Director Kaye Edward M. MD Reports Stock Sales and Option Grant

Director Kaye Edward M. MD reports sales of Stoke Therapeutics common stock to cover tax obligations and receives stock options and restricted stock units.

Summary

• On March 18, 2025, Director Kaye Edward M. MD sold 10,382 shares of Stoke Therapeutics common stock at a weighted average price of $8.67.
• The shares were sold in multiple transactions with prices ranging from $8.11 to $8.925 per share.
• On March 19, 2025, the director sold 8,907 shares at a weighted average price of $8.27, with prices ranging from $8.06 to $8.95 per share.
• Following these transactions, the director beneficially owns 139,346 shares of common stock.
• On March 20, 2025, the director was granted options to purchase 216,000 shares of common stock at an exercise price of $8.33, vesting monthly starting April 15, 2025, and expiring on March 19, 2035.
• The director also received 144,000 restricted stock units (RSUs), vesting annually beginning on March 15, 2026, and settling into common stock on March 20, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock sales are related to tax obligations, and the grants are part of standard compensation practices. There is no indication of unusual activity or concern.

Positives

• The grant of stock options and restricted stock units to the director aligns their interests with those of the shareholders.

Future Outlook

The director's stock options vest monthly starting April 15, 2025, and the restricted stock units vest annually beginning March 15, 2026, contingent on continued service to the issuer.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices for directors in publicly traded biotechnology companies like Stoke Therapeutics.
• The vesting schedules and exercise prices are generally in line with industry standards for incentivizing long-term performance.
• Comparable companies include Wave Life Sciences, Sarepta Therapeutics, and Ionis Pharmaceuticals, which also utilize stock-based compensation for their directors and executives.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but this is likely offset by the director's continued ownership and the incentive provided by the stock options and RSUs.

Key Dates

Keywords

Stoke Therapeutics, STOK, Director, Stock Sale, Stock Options, Restricted Stock Units, Form 4